Anti-Microbial Savior BioteQ Co., Ltd. (TPEX:6864)
Taiwan · Delayed Price · Currency is TWD 49.45
-1.05 (-2.08%)
Sep 15, 2026, 1:40 PM CST
TPEX:6864 Revenue
Anti-Microbial Savior BioteQ had revenue of 842.00K TWD in the half year ending June 30, 2026, with 57.38% growth. This brings the company's revenue in the last twelve months to 1.26M, up 115.23% year-over-year. In the year 2025, Anti-Microbial Savior BioteQ had annual revenue of 706.00K with 15.36% growth.
Revenue (ttm)
1.26M
Revenue Growth
+115.23%
P/S Ratio
1,520.42
Revenue / Employee
38.12K
Employees
33
Market Cap
1.91B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 706.00K | 94.00K | 15.36% |
| Dec 31, 2024 | 612.00K | -116.00K | -15.93% |
| Dec 31, 2023 | 728.00K | -1.97M | -73.01% |
| Dec 31, 2022 | 2.70M | 2.61M | 2,964.77% |
| Dec 31, 2021 | 88.00K | 15.00K | 20.55% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GenMont Biotech Incorporation | 382.11M |
| Abnova (Taiwan) | 345.45M |
| NeoCore Technology | 277.54M |
| Enimmune | 53.45M |
| Holy Stone Healthcare | 47.51M |
| TaiRx | 29.44M |